A phase II study of tandutinib (MLN518) in androgen-independent prostate cancer with bone metastases.

Trial Profile

A phase II study of tandutinib (MLN518) in androgen-independent prostate cancer with bone metastases.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Tandutinib (Primary)
  • Indications Bone metastases; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Feb 2008 Status changed from recruiting to in progress according to NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top